|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
Cystic Fibrosis (CF) is an inherited chronic disease caused by a gene defect. It is estimated to occur in about 1 in every 3500 children born in the United States. This complex disease can affect the lungs, the digestive system, and other organs resulting in a high morbidity and mortality. CF can also affect the pharmacokinetics of many drugs and this needs to be considered when prescribing medications to CF patients. CF has no known cure, but treatments are available to help modify the disease process. The modules of this program will provide information on the disease and treatments for the CF patient as well as address other important challenges and considerations in CF patients. The modules of this program will provide information on the disease and treatments for the CF patient as well as address other important challenges and considerations in CF patients. Module 1 will provide an overview of CF disease. The metabolism differences to consider in CF patients will also be addressed.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Describe the basic pathophysiology of cystic fibrosis (CF) & the organs affected
- List two differences in drug metabolism in patients with CF
- Briefly discuss the medications utilized in CF patients with CF
Jeffery T. Zobell, PharmD, BCPPS
Advanced Clinical Pharmacist
Intermountain Primary Children's Hospital
Intermountain Cystic Fibrosis Pediatric Center
Salt Lake City, Utah
Email Contact: [email protected]
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Jeffery Zobell does not have any relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 02-13-2017
Expiration Date: 02-13-2020
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-078-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.